<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686825</url>
  </required_header>
  <id_info>
    <org_study_id>DA8010_DIF_I</org_study_id>
    <nct_id>NCT04686825</nct_id>
  </id_info>
  <brief_title>The Food Effect on Pharmacokinetics of DA-8010 After a Single Administration of DA-8010 2.5 mg or 5 mg in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, 4-way Crossover Phase 1 Study to Evaluate the Food Effect on Pharmacokinetics of DA-8010 After a Single Administration of DA-8010 2.5 mg or 5 mg in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, single-dose, 4-way crossover phase 1 study to evaluate the&#xD;
      food effect on pharmacokinetics of DA-8010 after a single administration of DA-8010 2.5 mg or&#xD;
      5 mg under fasting and fed states in healthy male and female subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Actual">March 11, 2021</completion_date>
  <primary_completion_date type="Actual">February 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>0~48hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUClast)</measure>
    <time_frame>0~48hours</time_frame>
    <description>PK parameter</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-8010 2.5 mg (Fasting)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-8010 2.5 mg (Fed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-8010 5 mg (Fasting)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-8010 5 mg (Fed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-8010 2.5mg (Fasting)</intervention_name>
    <description>Test drug l : DA-8010 2.5mg (Fasting)</description>
    <arm_group_label>T1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-8010 2.5mg (Fed)</intervention_name>
    <description>Test drug ll : DA-8010 2.5mg (Fed)</description>
    <arm_group_label>T2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-8010 5mg (Fasting)</intervention_name>
    <description>Test drug llI : DA-8010 5mg (Fasting)</description>
    <arm_group_label>T3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-8010 5mg (Fed)</intervention_name>
    <description>Test drug lV : DA-8010 5mg (Fed)</description>
    <arm_group_label>T4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female volunteer 19 years to 50 years&#xD;
&#xD;
          -  Body weight in the range of 45.0 to 90.0 kg and body mass index in the range of 18 to&#xD;
             30kg/m2&#xD;
&#xD;
          -  The subjects personally signed and dated informed consent document after informed of&#xD;
             all patient aspects of the study, fully understanding and determined spontaneously to&#xD;
             participate&#xD;
&#xD;
          -  The subjects who are judged appropriate to participate this clinical trial according&#xD;
             to the physical examination, routine laboratory examination and questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with serious active hepatobiliary (severe hepatic failure, etc.), renal(severe&#xD;
             renal impairment, etc.), neurologic, immunologic, respiratory, digestive, endocrine,&#xD;
             hematologic, cardiovascular(heart failure, Torsades de pointes, etc), urologic,&#xD;
             psychological disease or history of such disease&#xD;
&#xD;
          -  Subject Hypersensitive to any of the IP components or other drug components(Aspirin,&#xD;
             Antibiotics, etc.)&#xD;
&#xD;
          -  Subject with gastrointestinal disease (peptic ulcer, gastritis, gastrospasm,&#xD;
             gastroesophageal reflux disease, Crohn's disease, etc.) or history of such&#xD;
             disease/surgery (excluding simple appendic surgery, hernia surgery, hemorrhoid&#xD;
             surgery)&#xD;
&#xD;
          -  Subject who have blood pressure &lt; 90 mmHg or &gt;150 mmHg as systolic or &lt;60 mmHg or &gt;100&#xD;
             mmHg as diastolic&#xD;
&#xD;
          -  Subject who have history of drug abuse or Positive in Urine drug screen test&#xD;
&#xD;
          -  Subject who are Positivie in Alcohol breath test on screening&#xD;
&#xD;
          -  Subject who have ETC drug or oriental medicine 2 weeks prior to IP administration or&#xD;
             OTC drug or health functional food or vitamins 1 week prior to IP administration&#xD;
&#xD;
          -  Subject who have taken a drug that induces or inhibits the drug metabolic enzyme&#xD;
             (e.g., barbital) within 30 days prior to IP administration&#xD;
&#xD;
          -  Subject who have participated in other clinical trials within 6 months prior to the&#xD;
             first administration of the IP&#xD;
&#xD;
          -  Subject who have had whole blood transfusion within 2 months or the apheresis within 2&#xD;
             weeks prior to the first administration of the IP&#xD;
&#xD;
          -  Subject with a history of regular alcohol intake(&gt;21 units/week , 1 unit = 10 g of&#xD;
             pure alcohol) or who are unable to quit alcohol from 3 days prior to the first&#xD;
             administration of the IP until out of hospital&#xD;
&#xD;
          -  Smoker(excluding who quit smoking 3 months before this clinical trial) or subject who&#xD;
             are unable to quit smoking from 3 days prior to first administration of the IP until&#xD;
             out of hospital&#xD;
&#xD;
          -  Subject who are unable to quit food containing grapefruit from 3 days before first&#xD;
             administration of the IP until out of hospital&#xD;
&#xD;
          -  Subject who regularly intake caffeine(&gt; 5 units/day) or who are unable to quit&#xD;
             caffeine/food containing caffeine from 3 days before first administration of the IP&#xD;
             until out of hospital&#xD;
&#xD;
          -  Subject with unusual eating habits (continuous vegetarian diet, etc.) or who are&#xD;
             unable to consume the entire diet provided in this clinical trial&#xD;
&#xD;
          -  Subject who are positive in pregnancy test or pregnant or Lactating women&#xD;
&#xD;
          -  Subject who do not agree to exclude the possibility of pregnancy using the&#xD;
             contraception from the date of the first administration of the IP until the 4 weeks&#xD;
             after the last administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung Hwan Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNUH Clinical Pharmacololgy and Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>DA-8010</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

